January 5, 2016 /
By
AUSTEN HUFFORD
Teva Pharmaceutical Industries Ltd. and Active Biotech AB said Monday they were ending the higher-dose portions of two multiple-sclerosis studies with the drug Laquinimod after eight patients suffered nonfatal cardiovascular events.
The companies said the incidents occurred in the higher-dose components of a phase 3 and a phase 2 clinical trial. The lower-dose and placebo components of the tests will continue.
Phase 3 clinical trials are typically the last phase before a drug gets approval from the U.S. Food and Drug Administration.
Laquinimod is a once-daily oral drug being developed for treating multiple sclerosis and Huntington disease.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News
helps to provide educational information for persons affected by MS
helps to provide educational information for persons affected by MS
Keep current with Multiple Sclerosis news and information
by opting-in to our website: click here – thank you
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
